Dr. Weng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
810 Bestgate Rd #400
Annapolis, MD 21401Phone+1 410-897-6200Fax+1 410-266-7636
Summary
- Dr. David Weng is an oncologist in the Baltimore-Washington DC area with Maryland Oncology Hematology. He received his undergraduate degree from Harvard College, medical degree and Ph.D from Johns Hopkins University School of Medicine. He did his medical oncology fellowship at the NIH. He is board certified and treats all solid tumor and hematologic malignancies. He is particularly experienced in the care of patients with breast cancer, GI cancer, lung cancer, gynecologic cancer, multiple myeloma, and lymphomas. He also has significant expertise for symptom management care. He has an extensive background in cancer translational and clinical research. His career activities have included substantial experiences in government, academic, biotechnology and community practice settings.
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
- Johns Hopkins UniversityResidency, Internal Medicine, 1992 - 1995
- Johns Hopkins University School of MedicineClass of 1992
- Harvard UniversityAB, Biochemistry, Magna Cum Laude, 1980 - 1984
Certifications & Licensure
- CA State Medical License 2013 - 2026
- MD State Medical License 1995 - 2025
- OH State Medical License 1998 - 2025
- American Board of Internal Medicine Medical Oncology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer Start of enrollment: 2008 Apr 01
Publications & Presentations
PubMed
- 52 citationsInhibition of the conversion of 3T3 fibroblast clones to adipocytes by dehydroepiandrosterone and related anticarcinogenic steroids.Gary B. Gordon, John A. Newitt, Lisa M. Shantz, David Weng, Paul Talalay
Cancer Research. 1986-07-01 - 71 citationsAngiozyme: a novel angiogenesis inhibitor.David E. Weng, Nassim Usman
Current Oncology Reports. 2001-03-01 - 130 citationsBirinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.Christopher A. Benetatos, Yasuhiro Mitsuuchi, Jennifer M. Burns, Eric M. Neiman, Stephen M. Condon
Molecular Cancer Therapeutics. 2014-04-01
Press Mentions
- David Weng: We Created Maryland Oncology Hematology to Improve Oncology Care in This Community | COMMENTARYMarch 7th, 2021
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: